# ![@endpts Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::3460109487.png) @endpts Endpoints News

Endpoints News posts on X about ceo, novartis, $pfe, sanofi the most. They currently have [------] followers and [---] posts still getting attention that total [------] engagements in the last [--] hours.

### Engagements: [------] [#](/creator/twitter::3460109487/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::3460109487/c:line/m:interactions.svg)

- [--] Week [------] -29%
- [--] Month [-------] +120%
- [--] Months [-------] +101%
- [--] Year [-------] +203%

### Mentions: [--] [#](/creator/twitter::3460109487/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::3460109487/c:line/m:posts_active.svg)

- [--] Month [--] -37%
- [--] Months [---] +51%
- [--] Year [---] +140%

### Followers: [------] [#](/creator/twitter::3460109487/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::3460109487/c:line/m:followers.svg)

- [--] Week [------] +0.12%
- [--] Month [------] +0.49%
- [--] Months [------] +3%
- [--] Year [------] +6.20%

### CreatorRank: [-------] [#](/creator/twitter::3460109487/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::3460109487/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  36.84% [finance](/list/finance)  17.76% [countries](/list/countries)  2.63% [technology brands](/list/technology-brands)  1.97% [exchanges](/list/exchanges)  0.66% [travel destinations](/list/travel-destinations)  0.66% [vc firms](/list/vc-firms)  0.66% [celebrities](/list/celebrities)  0.66%

**Social topic influence**
[ceo](/topic/ceo) #824, [novartis](/topic/novartis) 5.26%, [$pfe](/topic/$pfe) 4.61%, [sanofi](/topic/sanofi) #60, [eli lilly](/topic/eli-lilly) 3.95%, [ipo](/topic/ipo) 3.29%, [acquisition](/topic/acquisition) 2.63%, [$abbv](/topic/$abbv) 2.63%, [china](/topic/china) 2.63%, [$6753t](/topic/$6753t) 1.97%

**Top accounts mentioned or mentioned by**
[@rlcscienceboss](/creator/undefined) [@armstrongdrew](/creator/undefined) [@shelbyjliv](/creator/undefined) [@adrianradocea](/creator/undefined) [@maxonwifi](/creator/undefined) [@wearehims](/creator/undefined) [@maxgelman](/creator/undefined) [@tsrandall](/creator/undefined) [@drgiroir](/creator/undefined) [@vijaypande](/creator/undefined) [@andrewedunn](/creator/undefined) [@ztracer](/creator/undefined) [@biorunup](/creator/undefined) [@johncendpts](/creator/undefined) [@billclinton](/creator/undefined) [@gileadsciences](/creator/undefined) [@arcellx](/creator/undefined) [@patientpersists](/creator/undefined) [@chris_darnielle](/creator/undefined) [@andrewe_dunn](/creator/undefined)

**Top assets mentioned**
[Novartis AG (NVS)](/topic/novartis) [Pfizer, Inc. (PFE)](/topic/$pfe) [Sanofi (SNY)](/topic/sanofi) [Eli Lilly and Company (LLY)](/topic/eli-lilly) [AbbVie Inc (ABBV)](/topic/$abbv) [PTC Therapeutics, Inc. (PTCT)](/topic/$ptct) [Structure Therapeutics Inc. (GPCR)](/topic/$gpcr) [Monte Rosa Therapeutics, Inc. (GLUE)](/topic/$glue)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Ultragenyx cuts [---] jobs 10% of its workforce following a tough [----]. https://endpoints.news/ultragenyx-to-lay-off-about-130-employees-after-rough-2025/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/ultragenyx-to-lay-off-about-130-employees-after-rough-2025/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2022290019768033444)  2026-02-13T12:41Z 31.2K followers, [----] engagements


"PTC Therapeutics has withdrawn its NDA resubmission for a Duchenne treatment after the FDA doubted the data would meet its effectiveness threshold. https://endpoints.news/ptc-therapeutics-withdraws-us-filing-for-troubled-duchenne-treatment-translarna/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/ptc-therapeutics-withdraws-us-filing-for-troubled-duchenne-treatment-translarna/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2022317331091746897)  2026-02-13T14:29Z 31.2K followers, [----] engagements


"Argenx stops late-stage trials of Vyvgart Hytrulo its thyroid eye disease candidate after an interim analysis found the studies were unlikely to succeed. https://endpoints.news/argenx-cans-thyroid-eye-disease-trials-of-vyvgart-hytrulo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/argenx-cans-thyroid-eye-disease-trials-of-vyvgart-hytrulo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2000587851893768413)  2025-12-15T15:24Z 31.2K followers, [----] engagements


"The first biotech acquisition of [----] is here: Amgen is buying Oxford spinout Dark Blue Therapeutics in a deal worth up to $840M adding a preclinical cancer drug to its pipeline. https://endpoints.news/amgen-to-acquire-dark-blue-therapeutics-for-up-to-840m/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/amgen-to-acquire-dark-blue-therapeutics-for-up-to-840m/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2008612260827328814)  2026-01-06T18:50Z 31.2K followers, [----] engagements


"#JPM26 Day [--] Yesterday we got an update from Amgen on its obesity shot MariTide and insights on the future of biopharma from Novo Nordisk's Mike Doustdar. We're reporting live: https://endpoints.news/jpm26-day-2-at-the-jp-morgan-healthcare-conference/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/jpm26-day-2-at-the-jp-morgan-healthcare-conference/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2011103179023499376)  2026-01-13T15:48Z 31.2K followers, [----] engagements


"Q&A: Bristol Myers CEO Chris Boerner talks megamergers the outlook under Trump in [----] and why brain health is shaping up as pharmas next frontier. https://endpoints.news/jpm26-qa-with-bristol-myers-squibb-ceo-chris-boerner-on-2026-outlook/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/jpm26-qa-with-bristol-myers-squibb-ceo-chris-boerner-on-2026-outlook/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2011455449821065421)  2026-01-14T15:08Z 31.2K followers, [----] engagements


"#JPM26 day 3: As the conference winds down were tracking updates from WuXi AppTec and AbbVie plus reactions from Lillys CEO who says hes unfazed by rising competition. Follow along for the latest from San Francisco. https://endpoints.news/jpm26-day-3-at-the-jp-morgan-healthcare-conference/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/jpm26-day-3-at-the-jp-morgan-healthcare-conference/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2011471665151021376)  2026-01-14T16:13Z 31.2K followers, [----] engagements


"#JPM26 takeaway GLP-1s are hot. Every time you mention GLP-1 Im going to charge you $5. Im going to donate it to I dont know an injured Canadian seals fund or something like that" Sandoz CEO Richard Saynor said. https://endpoints.news/jpm26-sandoz-ceo-on-ozempic-generic-launch-plans-for-2026/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/jpm26-sandoz-ceo-on-ozempic-generic-launch-plans-for-2026/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2012209181336523027)  2026-01-16T17:03Z 31.2K followers, [----] engagements


"Pfizer is selling its ViiV stake a specialist HIV company it created with GSK to Japan's Shionogi for $2.1B. https://endpoints.news/pfizer-to-depart-gsks-viiv-as-shionogi-doubles-its-stake/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/pfizer-to-depart-gsks-viiv-as-shionogi-doubles-its-stake/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2013729403465830568)  2026-01-20T21:44Z 31.2K followers, [----] engagements


"Bristol Myers signs T cell engager deal with Janux for $50M upfront. https://endpoints.news/bristol-myers-signs-deal-with-janux-on-t-cell-engager-for-50m-upfront/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/bristol-myers-signs-deal-with-janux-on-t-cell-engager-for-50m-upfront/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2014452000021156005)  2026-01-22T21:35Z 31.2K followers, [----] engagements


"💼In this week's Peer Review: Karin Bok becomes the latest ex-FDA deputy to move to Lilly; also FDA alum Amy Muhlberg takes over as AbbVie's director of US policy; and Angelini Pharma gets a new CEO. Read the full update: https://endpoints.news/former-fda-deputies-land-at-lilly-abbvie-italys-angelini-has-a-new-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/former-fda-deputies-land-at-lilly-abbvie-italys-angelini-has-a-new-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2014738429901209692)  2026-01-23T16:34Z 31.2K followers, [----] engagements


"Genmab won't enroll any new patients in its early-stage trial of ProfoundBio's cancer candidate. https://endpoints.news/genmab-halts-enrollment-for-cancer-drug-from-profoundbio-buyout/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/genmab-halts-enrollment-for-cancer-drug-from-profoundbio-buyout/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2015894460614263166)  2026-01-26T21:07Z 31.2K followers, [----] engagements


"The FDA has put two Regenxbio gene therapy trials on hold after a patient developed a brain tumor dealing a setback to the biotech as it awaits a key approval decision. https://endpoints.news/fda-suspends-regenxbio-gene-therapy-trials-after-patient-developed-brain-tumor/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/fda-suspends-regenxbio-gene-therapy-trials-after-patient-developed-brain-tumor/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2016608554535268693)  2026-01-28T20:25Z 31.2K followers, [----] engagements


"Sanofi says it has up to 15B to spend on deals this year with M&A and R&D key to easing the looming patent cliff for blockbuster Dupixent. https://endpoints.news/sanofi-says-its-e15b-dealmaking-budget-rd-spend-should-help-ease-looming-dupixent-patent-cliff/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sanofi-says-its-e15b-dealmaking-budget-rd-spend-should-help-ease-looming-dupixent-patent-cliff/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2016912963915977029)  2026-01-29T16:34Z 31.2K followers, [----] engagements


"AstraZeneca is paying $1.2B upfront for CSPC's long-acting obesity drugs part of its commitment to invest $15B in China by [----]. https://endpoints.news/astrazeneca-pays-1-2b-for-cspcs-long-acting-obesity-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/astrazeneca-pays-1-2b-for-cspcs-long-acting-obesity-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2017247397588427004)  2026-01-30T14:43Z 31.2K followers, [----] engagements


"Sanofi's rare disease drugs gets mixed results in late-stage trials with a win in Gaucher diseases and a loss in Fabry disease. https://endpoints.news/sanofis-venglustat-succeeds-in-phase-3-gaucher-trial-but-fails-separate-study-in-fabry-disease/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sanofis-venglustat-succeeds-in-phase-3-gaucher-trial-but-fails-separate-study-in-fabry-disease/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2018310184741786004)  2026-02-02T13:07Z 31.2K followers, [----] engagements


"Pfizer announced this morning that patients taking the Metsera-originated obesity injection lost 10.5% of their body weight in six months. But it wasn't enough to meet sky-high hopes. https://endpoints.news/pfizers-metsera-originated-monthly-glp-1-cuts-weight-by-10-5-at-six-months/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/pfizers-metsera-originated-monthly-glp-1-cuts-weight-by-10-5-at-six-months/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2018701326834638945)  2026-02-03T15:01Z 31.2K followers, [----] engagements


"The FDA has handed a CRL to AstraZeneca for its self-injectable candidate for Lupus one month after it was approved in Europe. https://endpoints.news/astrazeneca-gets-crl-for-prefilled-pen-version-of-lupus-drug-saphnelo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/astrazeneca-gets-crl-for-prefilled-pen-version-of-lupus-drug-saphnelo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2018719611429015962)  2026-02-03T16:13Z 31.2K followers, [----] engagements


"Eli Lilly beat sales expectations and is projecting major growth in [----] fueled by its tirzepatide franchise a sharp contrast to rival Novo Nordisks forecasted decline. https://endpoints.news/lilly-beats-sales-forecasts-plots-major-growth-in-2026-in-stark-contrast-to-novo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/lilly-beats-sales-forecasts-plots-major-growth-in-2026-in-stark-contrast-to-novo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2019084111202173420)  2026-02-04T16:22Z 31.2K followers, [---] engagements


"Veradermics pulled off a $256M upsized IPO for its oral version of Rogaine a debut that points to renewed investor appetite for biotech listings. https://endpoints.news/veradermics-lands-256m-ipo-for-oral-rogaine/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/veradermics-lands-256m-ipo-for-oral-rogaine/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2019139235564187727)  2026-02-04T20:01Z 31.2K followers, 38.1K engagements


"Flagship-backed Generate:Biomedicines has filed for an IPO just days after dosing its first Phase [--] patient setting up a major test for the AI biotech sector. https://endpoints.news/flagships-generatebiomedicines-files-for-ipo-pitching-ai-driven-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/flagships-generatebiomedicines-files-for-ipo-pitching-ai-driven-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2019490003340886155)  2026-02-05T19:15Z 31.1K followers, [----] engagements


"Eikons IPO may be the biggest biotech debut in two years but the sharp valuation reset shows how tough the public markets remain for big-name big-money biotechs and what the next wave could face. https://endpoints.news/eikon-ipo-analysis-big-biotech-names-big-valuation-cut/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/eikon-ipo-analysis-big-biotech-names-big-valuation-cut/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2019498208687222868)  2026-02-05T19:47Z 31.1K followers, [----] engagements


"Bristol Myers is drawing renewed investor interest as a wave of late-stage data readouts approaches with the company flagging multiple potential approvals and label expansions this year. https://endpoints.news/bristol-myers-draws-pipeline-excitement-as-several-data-readouts-near/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/bristol-myers-draws-pipeline-excitement-as-several-data-readouts-near/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2019517772435443980)  2026-02-05T21:05Z 31.2K followers, [----] engagements


"Priovant Therapeutics heads to Phase [--] trial for its immune skin disease candidate after "landmark transformative" success in Phase [--]. https://endpoints.news/roivant-spinout-priovant-touts-phase-2-brepocitinib-data-in-cutaneous-sarcoidosis/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/roivant-spinout-priovant-touts-phase-2-brepocitinib-data-in-cutaneous-sarcoidosis/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2019776289536717077)  2026-02-06T14:12Z 31.2K followers, [----] engagements


"🚨 US calls for investigation of @wearehims over GLP-1 drugs threatening 'decisive steps' Breaking news from @ShelbyJLiv https://endpoints.news/us-calls-for-doj-investigation-of-hims-over-glp-1-drugs/ https://endpoints.news/us-calls-for-doj-investigation-of-hims-over-glp-1-drugs/"  
[X Link](https://x.com/endpts/status/2019912272773005574)  2026-02-06T23:13Z 31.2K followers, [----] engagements


"Lilly is buying Orna for $2.4B the largest buyout of an in vivo cell therapy company to date. https://endpoints.news/lilly-joins-in-vivo-car-t-sprint-with-2-4b-orna-acquisition/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/lilly-joins-in-vivo-car-t-sprint-with-2-4b-orna-acquisition/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2020923701404078588)  2026-02-09T18:12Z 31.2K followers, [---] engagements


"AstraZeneca joins the race for obesity pills with an announcement of promising Phase [--] results for its oral GLP-1. https://endpoints.news/astrazenecas-obesity-pill-hits-in-phase-2-key-cancer-trials-pushed-back/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/astrazenecas-obesity-pill-hits-in-phase-2-key-cancer-trials-pushed-back/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2021239542372520028)  2026-02-10T15:07Z 31.2K followers, [----] engagements


"Is AstraZeneca on track to meet its $80B revenue target https://endpoints.news/is-astrazeneca-on-track-to-meet-its-80b-revenue-target/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/is-astrazeneca-on-track-to-meet-its-80b-revenue-target/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2021290867424657840)  2026-02-10T18:31Z 31.2K followers, [---] engagements


"Money keeps flowing for private obesity and MASH developers. Cascade is the latest biotech to receive a pool of capital about $72M. https://endpoints.news/shanghais-cascade-gets-72m-to-pursue-mash-obesity-and-diabetes-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/shanghais-cascade-gets-72m-to-pursue-mash-obesity-and-diabetes-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2021320644252549330)  2026-02-10T20:29Z 31.2K followers, [----] engagements


"💼In this week's Peer Review: Paul Hudson hands over the baton for Sanofi's leadership to Beln Garijo adding to the flurry of CEO changes in big pharma. https://endpoints.news/paul-hudson-couldnt-quite-get-sanofi-over-the-hump-protac-developer-arvinas-appoints-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/paul-hudson-couldnt-quite-get-sanofi-over-the-hump-protac-developer-arvinas-appoints-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2022339383781896360)  2026-02-13T15:57Z 31.2K followers, [---] engagements


"Moderna is noncommittal on [----] break-even guidance after the FDA declined to review its flu shot. https://endpoints.news/modernas-flu-shot-dilemma-muddies-2028-break-even-guidance/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/modernas-flu-shot-dilemma-muddies-2028-break-even-guidance/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2022394355143909567)  2026-02-13T19:36Z 31.2K followers, [----] engagements


"Amgen is pulling out of its immunology drug collaboration with Kyowa Kirin. The news comes as a surprise after the companies reported encouraging results and prepared for submission later this year. https://endpoints.news/amgen-ends-partnership-with-kyowa-kirin-on-immunology-drug-despite-phase-3-wins/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/amgen-ends-partnership-with-kyowa-kirin-on-immunology-drug-despite-phase-3-wins/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2017301117890117866)  2026-01-30T18:17Z 31.2K followers, [----] engagements


"🚨 Moderna accuses FDA of shifting trial standard after agency refuses to review flu shot https://endpoints.news/moderna-accuses-fda-of-shifting-standard-as-agency-refuses-flu-shot-review/ https://endpoints.news/moderna-accuses-fda-of-shifting-standard-as-agency-refuses-flu-shot-review/"  
[X Link](https://x.com/endpts/status/2021365700997120053)  2026-02-10T23:28Z 31.2K followers, [----] engagements


"Upstream Bio said its TSLP-targeting drug cut severe asthma flare-ups by 56% in a Phase [--] trial. https://endpoints.news/upstream-bio-says-verekitug-delivered-positive-data-in-phase-2-severe-asthma-trial/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/upstream-bio-says-verekitug-delivered-positive-data-in-phase-2-severe-asthma-trial/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2021638490321215550)  2026-02-11T17:32Z 31.2K followers, [----] engagements


"Clinical trials are getting more complex and more expensive with redundant standards and mounting data demands driving up costs just as China moves faster and cheaper. Endpoints @MaxGelman dives into the problem in todays Endpoints in Focus. https://endpoints.news/how-a-closet-full-of-ekg-machines-illustrates-pharmas-clinical-trial-cost-problem/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2021681135323902241)  2026-02-11T20:21Z 31.2K followers, [----] engagements


"Structure Therapeutics oral GLP-1 hit all endpoints in a pair of mid-stage studies evaluating weight loss and safety sending its stock $GPCR up nearly 55% on Monday morning. https://endpts.com/structures-oral-glp-1-produces-comparable-weight-loss-to-lillys-oral-candidate/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term= https://endpts.com/structures-oral-glp-1-produces-comparable-weight-loss-to-lillys-oral-candidate/utm_medium=organic_social&utm_campaign=gatedarticle&utm_source=twitter&utm_content=&utm_term="  
[X Link](https://x.com/endpts/status/1797667148967592318)  2024-06-03T16:30Z 31.2K followers, [----] engagements


"Amicus reveals that it had another suitor before making a $4.8B deal to sell itself to BioMarin. https://endpoints.news/another-biopharma-tried-buying-amicus-before-biomarins-4-8b-deal/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/another-biopharma-tried-buying-amicus-before-biomarins-4-8b-deal/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2014439826934690262)  2026-01-22T20:47Z 31.2K followers, [----] engagements


"🎙Post-Hoc Live today at 12pm ET: The big showdown between drugmakers and compounders is finally here.🥊 Join @ArmstrongDrew and @ShelbyJLiv as they dissect Hims' decision to sell low-cost GLP-1s. 🥊 https://endpoints.news/post-hoc-live-analyzing-the-novo-vs-hims-glp-1-showdown/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/post-hoc-live-analyzing-the-novo-vs-hims-glp-1-showdown/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2019802031100231851)  2026-02-06T15:55Z 31.2K followers, [---] engagements


"Biotech IPOs are back in force: Agomab and SpyGlass are set to go public capping the biggest week for biotech listings since [----] with nearly $1B raised across four debuts. https://endpoints.news/agomab-spyglass-cap-biggest-week-for-biotech-ipos-since-2021/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/agomab-spyglass-cap-biggest-week-for-biotech-ipos-since-2021/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2019850785790583069)  2026-02-06T19:08Z 31.2K followers, [----] engagements


"FDA vaccines chief Vinay Prasad overruled agency reviewers in the decision not to review Modernas flu shot application according to a source familiar with the matter. https://endpoints.news/prasad-overruled-vaccine-review-team-office-director-on-moderna-flu-shot/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/prasad-overruled-vaccine-review-team-office-director-on-moderna-flu-shot/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2021662979469849033)  2026-02-11T19:09Z 31.2K followers, [----] engagements


"Madrigal Pharmaceuticals struck a deal with China-based Suzhou Ribo Life Science for six preclinical siRNAs in MASH paying $60M upfront as it builds out a next-generation pipeline around Rezdiffra. https://endpoints.news/madrigal-pads-mash-pipeline-with-six-sirnas-from-chinas-ribo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/madrigal-pads-mash-pipeline-with-six-sirnas-from-chinas-ribo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2021698441672323392)  2026-02-11T21:30Z 31.2K followers, [----] engagements


"In a first for the field Lyell has launched a head-to-head Phase [--] trial pitting its CAR-T therapy directly against approved rivals marking a new chapter in how cell therapies are tested. https://endpoints.news/lyell-starts-first-head-to-head-car-t-therapy-trial/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/lyell-starts-first-head-to-head-car-t-therapy-trial/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2021945108397273470)  2026-02-12T13:50Z 31.2K followers, [----] engagements


"Sanofis incoming CEO Beln Garijo got a frosty market welcome with shares sliding as investors weigh the looming Dupixent patent cliff and questions about pipeline execution. https://endpoints.news/sanofis-new-ceo-belen-garijo-gets-frosty-reception-as-challenges-await/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sanofis-new-ceo-belen-garijo-gets-frosty-reception-as-challenges-await/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2021995278820421836)  2026-02-12T17:10Z 31.2K followers, [---] engagements


"Even Europeans arent betting on Europe. @tsrandall reports that in Endpoints Signals latest survey just 9% of industry pros and only 24% of Europeans said theyd start their career there as R&D and optimism shift to the US and China. https://endpoints.news/even-europeans-dont-see-a-future-in-euro-biopharma-anymore/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/even-europeans-dont-see-a-future-in-euro-biopharma-anymore/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2022054610417201509)  2026-02-12T21:06Z 31.2K followers, [---] engagements


"Novartis expects generics to cut about $4B from [----] sales with Entresto taking a sharp hit in Q4 as competition ramps up. https://endpoints.news/novartis-says-generics-to-erode-4b-from-2026-sales/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novartis-says-generics-to-erode-4b-from-2026-sales/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2019094876063695105)  2026-02-04T17:05Z 31.2K followers, [----] engagements


"🚨 Novo Nordisk is suing Hims for patent infringement of its semaglutide in both pill and injectable form. Last week Hims announced a compounded version of Wegovy pill (Novo's GLP-1) before reversing course on Saturday. https://endpoints.news/novo-nordisk-sues-hims-over-wegovy-patent-infringement-considers-seeking-hundreds-of-millions-in-damages/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2020857504574415046)  2026-02-09T13:49Z 31.2K followers, [----] engagements


"#ACTRIMS26 Sanofi reveals confluence of factors that led to the failure of late-stage MS trial. https://endpoints.news/actrims26-sanofi-unpacks-data-from-a-failed-phase-3-tolebrutinib-trial-in-ppms/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/actrims26-sanofi-unpacks-data-from-a-failed-phase-3-tolebrutinib-trial-in-ppms/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2020870095984091514)  2026-02-09T14:39Z 31.2K followers, [----] engagements


"Exclusive: Sanofi is investing $30M in GluBio Therapeutics a US-China startup developing molecular glue drugs for certain inherited blood disorders. https://endpoints.news/sanofi-invests-in-china-startup-developing-molecular-glue-for-sickle-cell/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sanofi-invests-in-china-startup-developing-molecular-glue-for-sickle-cell/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2021601134243135650)  2026-02-11T15:04Z 31.2K followers, [----] engagements


"Sanofi is replacing CEO Paul Hudson with Merck KGaAs Beln Garijo who will take the helm as the pharma faces pipeline setbacks and looming biosimilar pressure on Dupixent. https://endpoints.news/sanofis-paul-hudson-out-as-belen-garijo-steps-in-as-new-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sanofis-paul-hudson-out-as-belen-garijo-steps-in-as-new-ceo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2021972373667557776)  2026-02-12T15:39Z 31.2K followers, [----] engagements


"Controversy is mounting around FDA vaccines chief Vinay Prasad following the agencys rejection of Modernas flu shot and new reports of internal personnel complaints. https://endpoints.news/controversy-around-fdas-prasad-rises-again-after-moderna-rejection-behavior-allegations/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/controversy-around-fdas-prasad-rises-again-after-moderna-rejection-behavior-allegations/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2022037278047240658)  2026-02-12T19:57Z 31.2K followers, [----] engagements


"CRISPR pioneer Feng Zhang's company is pivoting into siRNA obesity therapies. "If you can do it with siRNA its really hard to argue you should do it some other way" Moonwalk's CEO told @RLCscienceboss. https://endpoints.news/epigenetic-editing-startup-moonwalk-shifts-focus-to-sirna-for-obesity/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/epigenetic-editing-startup-moonwalk-shifts-focus-to-sirna-for-obesity/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2022377459484664289)  2026-02-13T18:28Z 31.2K followers, 34.9K engagements


"Lundbeck scored a big win for its migraine prevention candidate. The Danish company could now go into late-stage trials this year. https://endpoints.news/lundbeck-migraine-prevention-drug-succeeds-in-phase-2-advancing-new-therapy-class/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/lundbeck-migraine-prevention-drug-succeeds-in-phase-2-advancing-new-therapy-class/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/2022422958334185739)  2026-02-13T21:29Z 31.2K followers, [---] engagements


"After years of hype are drugs-in-space ready for liftoff 🚀Join Varda CSO @adrian_radocea Endpoints @ArmstrongDrew & @RLCscienceboss live on July [--] at 12:15 p.m. ET to discuss biopharmas orbital ambitions. https://endpoints.news/endpoints-livestream-drugs-and-biomanufacturing-in-space-with-varda-cso-adrian-radocea/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/endpoints-livestream-drugs-and-biomanufacturing-in-space-with-varda-cso-adrian-radocea/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1945544279826346158)  2025-07-16T18:01Z 30K followers, [----] engagements


"Novartis raised its full-year [----] outlook after Q2 sales rose about 11% to $14B. The company also announced a $10B share buyback. https://endpoints.news/novartis-ups-income-guidance-initiates-10b-share-buyback/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novartis-ups-income-guidance-initiates-10b-share-buyback/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1945845761297572199)  2025-07-17T13:59Z 30K followers, [---] engagements


"In case you missed it Varda Space Industries' CSO @adrian_radocea came to Post-Hoc Live last week to discuss what happens when drugs are formulated in orbit and come back down to earth. Watch it here: https://www.youtube.com/live/sZ_Ow1dXq-Yutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://www.youtube.com/live/sZ_Ow1dXq-Yutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1947277551027601753)  2025-07-21T12:48Z 30.1K followers, [----] engagements


"Stealthy startup Orbital just pulled back the curtain on its mRNA pipeline sharing exclusive details on their preclinical data with @RLCscienceboss. https://endpoints.news/circular-rna-startup-orbital-unveils-first-monkey-data-as-it-enters-in-vivo-car-t-cell-therapy-race/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/circular-rna-startup-orbital-unveils-first-monkey-data-as-it-enters-in-vivo-car-t-cell-therapy-race/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1948006077850648870)  2025-07-23T13:03Z 30.1K followers, [----] engagements


"Dispatch Bio launched with $216M to take on solid tumors using CAR-T. Backed by ARCH and the Parker Institute and led by pioneers like Carl June the startup aims to expand the reach of cell therapy. https://endpoints.news/parker-institute-arch-unveil-car-t-biotech-with-216m-to-crack-solid-tumors/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/parker-institute-arch-unveil-car-t-biotech-with-216m-to-crack-solid-tumors/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1948025259774591126)  2025-07-23T14:19Z 30.4K followers, [----] engagements


"Abivax shares jumped more than 400% after its ulcerative colitis drug obefazimod met Phase [--] goals in two trials showing remission benefits in hard-to-treat patients. https://endpoints.news/abivax-shares-up-over-400-as-ulcerative-colitis-drug-scores-two-phase-3-wins/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/abivax-shares-up-over-400-as-ulcerative-colitis-drug-scores-two-phase-3-wins/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1948059911574999399)  2025-07-23T16:37Z 30.1K followers, [---] engagements


"Galapagos is shaking things up again with new executives changes to its Gilead deal and a possible cell therapy sale. https://endpoints.news/still-in-flux-galapagos-hires-new-execs-adjusts-deal-with-gilead-and-considers-selling-its-cell-therapy-business/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/still-in-flux-galapagos-hires-new-execs-adjusts-deal-with-gilead-and-considers-selling-its-cell-therapy-business/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1948418239358206248)  2025-07-24T16:21Z 30.1K followers, [----] engagements


"Novartis is paying $60M upfront to partner with Matchpoint on covalent inhibitors for inflammation. The deal could reach up to $1B with milestones and includes an option for exclusive rights. https://endpoints.news/novartis-inks-deal-with-covalent-medicines-biotech-matchpoint-for-60m-upfront/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novartis-inks-deal-with-covalent-medicines-biotech-matchpoint-for-60m-upfront/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1948436373393809819)  2025-07-24T17:33Z 30.2K followers, [----] engagements


"Sarepta has paused Elevidys shipments following FDA safety concerns leaving families in limbo. With three patient deaths now linked to its gene therapies the biotech faces a major crisis. https://endpoints.news/how-sareptas-crisis-over-patient-deaths-unfolded-and-what-happens-next/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/how-sareptas-crisis-over-patient-deaths-unfolded-and-what-happens-next/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1948491970172584452)  2025-07-24T21:14Z 30.1K followers, [----] engagements


"Bristol Myers names Cristian Massacesi as new CMO replacing Samit Hirawat on Aug. [--]. The move comes as BMS reshapes its pipeline and tightens costs amid a pivotal transition. https://endpoints.news/bristol-myers-snags-cristian-massacesi-from-astrazeneca-as-its-new-chief-medical-officer/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/bristol-myers-snags-cristian-massacesi-from-astrazeneca-as-its-new-chief-medical-officer/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1948805951995478273)  2025-07-25T18:02Z 30.3K followers, [----] engagements


"Celcuitys breast cancer drug reduced the risk of progression or death by 67% in some patients in a Phase [--] trial setting up a potential challenge to Novartis and Roche. Shares jumped more than 200% on the data. https://endpoints.news/celcuity-posts-phase-3-win-in-breast-cancer-setting-up-challenge-to-novartis-and-roche/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/celcuity-posts-phase-3-win-in-breast-cancer-setting-up-challenge-to-novartis-and-roche/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1949872598180925766)  2025-07-28T16:40Z 30.2K followers, [----] engagements


"Merck has unveiled a $3B cost-cutting plan through [----] joining peers like Pfizer and BMS in scaling back spending. https://endpoints.news/merck-announces-3b-in-cost-cuts/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/merck-announces-3b-in-cost-cuts/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1950227647851880627)  2025-07-29T16:11Z 30.2K followers, [----] engagements


"Exclusive: Formation Bio has licensed its first drug since raising $372M an anti-CD226 antibody from IMIDomics and plans two more deals in [----] as it builds out its pipeline. https://endpoints.news/exclusive-formation-bio-licenses-imidomics-ibd-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/exclusive-formation-bio-licenses-imidomics-ibd-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1950250649058263278)  2025-07-29T17:42Z 30.5K followers, [----] engagements


"🚨 BREAKING: Vinay Prasad FDA's controversial head of vaccines and biologics is out https://endpoints.news/vinay-prasad-out-at-fda-after-agency-backtracks-on-sarepta-decision/ https://endpoints.news/vinay-prasad-out-at-fda-after-agency-backtracks-on-sarepta-decision/"  
[X Link](https://x.com/endpts/status/1950360174163583243)  2025-07-30T00:57Z 30.2K followers, 43.6K engagements


"Madrigal is paying $120M upfront to license a preclinical GLP-1 from Chinas CSPC with plans to target liver disease rather than obesity. The deal could total up to $2B. https://endpoints.news/madrigal-licenses-preclinical-glp-1-from-cspc-for-120m-upfront/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/madrigal-licenses-preclinical-glp-1-from-cspc-for-120m-upfront/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1950661583312695298)  2025-07-30T20:55Z 30.2K followers, [----] engagements


"New data suggest Lilly and Eisais Alzheimers drugs may offer greater benefits over time though the companies are taking different approaches to long-term use of their therapies. https://endpoints.news/new-data-for-alzheimers-drugs-raise-hopes-and-questions-about-bigger-benefits-over-time/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/new-data-for-alzheimers-drugs-raise-hopes-and-questions-about-bigger-benefits-over-time/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1950671882216194493)  2025-07-30T21:36Z 30.3K followers, [----] engagements


"Regeneron got another FDA rejection for its bispecific antibody this time due to issues at a site owned by Novo Nordisk. Regeneron also forecasts pending PDUFAs for Eylea HD could be delayed. https://endpoints.news/regeneron-gets-another-crl-predicts-delayed-august-pdufa-for-eylea-hd/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/regeneron-gets-another-crl-predicts-delayed-august-pdufa-for-eylea-hd/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1951307102971941244)  2025-08-01T15:40Z 30.2K followers, [----] engagements


"Biogen is launching a New Ventures team to invest in early-stage external research aiming to build relationships that it could one day bring in-house. https://endpoints.news/biogen-is-building-a-ventures-team-to-keep-early-portfolio-externalized/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/biogen-is-building-a-ventures-team-to-keep-early-portfolio-externalized/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1952381072429158724)  2025-08-04T14:48Z 30.2K followers, [----] engagements


"Pfizer CEO says drugmakers ready to work with Trump on DTC sales programs https://endpoints.news/pfizer-ceo-says-drugmakers-are-ready-to-work-with-trump-on-direct-sales-programutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/pfizer-ceo-says-drugmakers-are-ready-to-work-with-trump-on-direct-sales-programutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1952768886270464324)  2025-08-05T16:29Z 30.3K followers, [----] engagements


"Novo Nordisk has cut several programs before its new CEO begins. https://endpoints.news/novo-nordisks-pipeline-cull-prompts-hopes-of-strategic-shiftutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novo-nordisks-pipeline-cull-prompts-hopes-of-strategic-shiftutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1953119417602089323)  2025-08-06T15:42Z 30.2K followers, [----] engagements


"Kennedy says BARDA to cancel work on future mRNA vaccines citing they 'don't perform well'. https://endpoints.news/kennedy-says-barda-will-cancel-22-mrna-vaccine-contracts/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/kennedy-says-barda-will-cancel-22-mrna-vaccine-contracts/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1953188583151481038)  2025-08-06T20:17Z 30.2K followers, [----] engagements


"Lilly CEO David Ricks pushed back on Trumps drug pricing push warning it could hurt U.S. innovation just as underwhelming obesity pill data overshadowed a $15.6B Q2 revenue beat. https://endpoints.news/lillys-rise-in-revenue-clouded-by-phase-3-obesity-pill-readout/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/lillys-rise-in-revenue-clouded-by-phase-3-obesity-pill-readout/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1953525987829846460)  2025-08-07T18:37Z 30.2K followers, [----] engagements


"Novo is still leading the obesity pill race. Lillys orforglipron showed 11% weight loss in Phase [--] trailing Novos 13% in a comparable trial. https://endpoints.news/obesity-pill-comparison-how-novo-lilly-and-others-stack-up/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/obesity-pill-comparison-how-novo-lilly-and-others-stack-up/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1953548637650157940)  2025-08-07T20:07Z 30.2K followers, [----] engagements


"AbbVie and Genmabs Epkinly met both primary endpoints in a Phase [--] trial showing strong efficacy in second-line follicular lymphoma. https://endpoints.news/abbvie-and-genmab-seek-to-expand-use-of-t-cell-engager-epkinly/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/abbvie-and-genmab-seek-to-expand-use-of-t-cell-engager-epkinly/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1953846652080398408)  2025-08-08T15:51Z 30.5K followers, [----] engagements


"Novartis clears two Phase [--] studies in Sjgrens disease bringing a first-in-class drug one step closer to market. https://endpoints.news/novartis-antibody-drug-ianalumab-passes-two-phase-3-studies-in-sjogrens-disease/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novartis-antibody-drug-ianalumab-passes-two-phase-3-studies-in-sjogrens-disease/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1954905390128521533)  2025-08-11T13:59Z 30.3K followers, [----] engagements


"Today on Post-Hoc Live well talk to @DrGiroir the assistant secretary for health at HHS under the first Trump administration about the future of mRNA vaccines after RFK Jr.s recent cuts. Join us at 11:30 ET: https://endpoints.news/endpoints-livestream-what-rfks-exile-of-mrna-says-about-maha-and-biotech/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/endpoints-livestream-what-rfks-exile-of-mrna-says-about-maha-and-biotech/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1955249740271992852)  2025-08-12T12:47Z 30.2K followers, [---] engagements


"RFK Jr.'s mRNA funding cuts aren't justified Admiral Brett Giroir former US bio-preparedness official said on Post-Hoc Live. "I thought the whole premise was wrong. The facts that were stated were not facts at all.""  
[X Link](https://x.com/endpts/status/1955690063146483961)  2025-08-13T17:57Z 30.3K followers, [----] engagements


"Eli Lilly and Superluminal partner up in an obesity deal worth up to $1.3B. https://endpoints.news/lilly-gets-another-obesity-partner-in-deal-with-superluminal-worth-up-to-1-3b/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/lilly-gets-another-obesity-partner-in-deal-with-superluminal-worth-up-to-1-3b/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1956100731053715637)  2025-08-14T21:08Z 30.3K followers, [----] engagements


"Pharma "will not relent" in the fight against IRA as AstraZeneca potentially readies to appeal to the Supreme Court. https://endpoints.news/pharmas-ira-fight-persists-as-it-looks-to-supreme-court-lobbies-for-changes/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/pharmas-ira-fight-persists-as-it-looks-to-supreme-court-lobbies-for-changes/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1956329651120312780)  2025-08-15T12:18Z 30.3K followers, [----] engagements


"Annoca has announced securing $46M to run an early stage TCR cell therapy trial. https://endpoints.news/anocca-gets-46m-to-run-early-tcr-cell-therapy-clinical-trial/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/anocca-gets-46m-to-run-early-tcr-cell-therapy-clinical-trial/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1957413435207000402)  2025-08-18T12:05Z 30.3K followers, [----] engagements


"Gene therapy biotech raises $313M to develop treatments for eye diseases metabolic disorders and neurological conditions. https://endpoints.news/gene-therapy-startup-kriya-therapeutics-gets-313m/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/gene-therapy-startup-kriya-therapeutics-gets-313m/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1957451245213409597)  2025-08-18T14:35Z 30.4K followers, [----] engagements


"Skyhawk inks another deal this time with Merck KGaA in a pact estimated to be worth more than $2B. https://endpoints.news/skyhawks-rna-mission-gets-another-2b-lift-via-merck-kgaa/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/skyhawks-rna-mission-gets-another-2b-lift-via-merck-kgaa/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1957521882603045158)  2025-08-18T19:16Z 30.3K followers, [----] engagements


"Enanta has filed a new patent lawsuit in EU court alleging that Pfizers Paxlovid infringes its protease inhibitor intellectual property. https://endpoints.news/enanta-files-patent-suit-against-pfizer-in-europe/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/enanta-files-patent-suit-against-pfizer-in-europe/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1958563281536217212)  2025-08-21T16:14Z 30.3K followers, [----] engagements


"Gilead is moving into in vivo cell therapy with a $350M buyout of Interius aiming to make CAR-T more scalable. https://endpoints.news/gilead-joins-the-in-vivo-cell-therapy-race-with-350m-buyout-of-interius/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/gilead-joins-the-in-vivo-cell-therapy-race-with-350m-buyout-of-interius/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1958606474655277141)  2025-08-21T19:05Z 30.3K followers, [----] engagements


"The FDA has approved Ionis Dawnzera the first RNA-targeting therapy for hereditary angioedema. https://endpoints.news/fda-approves-ionis-rna-targeting-therapy-to-treat-rare-disease-that-causes-swelling-attacks/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/fda-approves-ionis-rna-targeting-therapy-to-treat-rare-disease-that-causes-swelling-attacks/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1958628099178078221)  2025-08-21T20:31Z 30.4K followers, [----] engagements


"Exclusive:OpenAI and Retro Bio have teamed up to test AI-designed proteins from a mini GPT-4 model. Early lab data show a 50-fold boost in stem cell reprogramming with drug development up next. https://endpoints.news/openai-retro-bio-detail-results-of-ai-model-for-proteinsutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/openai-retro-bio-detail-results-of-ai-model-for-proteinsutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1958991697985380854)  2025-08-22T20:36Z 30.3K followers, [----] engagements


"Merck is leaning on its $5B HIV pipeline as the Keytruda patent cliff approaches. https://endpoints.news/merck-looks-to-modest-hiv-business-as-a-5b-underdog/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/merck-looks-to-modest-hiv-business-as-a-5b-underdog/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1960063106891300959)  2025-08-25T19:33Z 30.3K followers, [----] engagements


"Eli Lilly is "moving with urgency" to file for worldwide approval of its new oral GLP-1 after data shows patients with obesity and diabetes T2 lose close to 10% of body weight. https://endpoints.news/lilly-plans-glp-1-pill-filing-after-trial-success-in-obesity-and-diabetes/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/lilly-plans-glp-1-pill-filing-after-trial-success-in-obesity-and-diabetes/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1960320111488733342)  2025-08-26T12:35Z 30.4K followers, [----] engagements


"The Trump administration has ousted CDC Director Susan Monarez just weeks after her confirmation. Several other top CDC officials also resigned on Wednesday in protest. https://endpoints.news/cdc-director-susan-monarez-suddenly-departs-weeks-into-the-role/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/cdc-director-susan-monarez-suddenly-departs-weeks-into-the-role/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1961077728578306310)  2025-08-28T14:45Z 30.3K followers, [---] engagements


"Single-asset deals are the hot choice this year. Lilly Sanofi GSK and AbbVie are all taking this approach as drugmakers get creative in an ever more competitive market. https://endpoints.news/abbvies-gilgamesh-deal-highlights-pharmas-one-asset-mind/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/abbvies-gilgamesh-deal-highlights-pharmas-one-asset-mind/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1961406839364407626)  2025-08-29T12:33Z 30.4K followers, [----] engagements


"Charm Therapeutics Nvidia backed start-up co-founded by Nobel laureate David Baker has raised $80M to bring to clinic a cancer drug designed with AI. https://endpoints.news/nvidia-backed-charm-therapeutics-gets-80m-to-take-ai-designed-cancer-drug-to-clinic/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/nvidia-backed-charm-therapeutics-gets-80m-to-take-ai-designed-cancer-drug-to-clinic/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1962969648107798669)  2025-09-02T20:03Z 30.4K followers, [----] engagements


"Novartis is doubling down on siRNA with a second deal with Argo Biopharma worth up to $5.2B. https://endpoints.news/novartis-signs-one-of-the-years-largest-biobuck-deals-with-shanghai-biotech-argo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novartis-signs-one-of-the-years-largest-biobuck-deals-with-shanghai-biotech-argo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1963317574394888364)  2025-09-03T19:06Z 30.4K followers, [----] engagements


"Pfizer CEO Albert Bourla defended the Covid-19 vaccine after Trumps remarks calling Operation Warp Speed a major public health success and highlighting mRNAs potential in cancer. https://endpoints.news/pfizer-ceo-responds-to-trumps-questioning-of-covid-data/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/pfizer-ceo-responds-to-trumps-questioning-of-covid-data/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1963337021143109778)  2025-09-03T20:23Z 30.4K followers, [----] engagements


"Sanofis amlitelimab fell short in a Phase [--] eczema trial with skin clearance rates lagging behind Dupixent. Shares slipped on the underwhelming topline data. https://endpoints.news/sanofi-shares-take-a-hit-from-subpar-phase-3-eczema-data/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sanofi-shares-take-a-hit-from-subpar-phase-3-eczema-data/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1963626660063838631)  2025-09-04T15:34Z 30.4K followers, [----] engagements


"Eli Lilly is offering startups free access to its AI models in exchange of data. https://endpoints.news/eli-lilly-offers-ai-models-to-biotechs-with-tunelab-launch/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/eli-lilly-offers-ai-models-to-biotechs-with-tunelab-launch/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1965410131145093131)  2025-09-09T13:41Z 30.4K followers, [----] engagements


"Novo Nordisk will cut [----] jobs following recent leadership changes including the departure of its CEO. https://endpoints.news/novo-nordisk-to-cut-9000-jobs-posts-another-profit-warning-as-it-refocuses-on-core-meds/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novo-nordisk-to-cut-9000-jobs-posts-another-profit-warning-as-it-refocuses-on-core-meds/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1965841678838940151)  2025-09-10T18:15Z 30.4K followers, [----] engagements


"After shelving its IPO Odyssey raised $213M in a Series D topping expectations as it leans on private markets to fund its immunology pipeline. https://endpoints.news/odyssey-gets-213m-series-d-after-backing-out-of-ipo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/odyssey-gets-213m-series-d-after-backing-out-of-ipo/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1965860118253416742)  2025-09-10T19:29Z 30.4K followers, [----] engagements


"Exclusive: Medra led by first-time founder Michelle Lee aims to automate 70% of lab work using robotics and AI. Shes raised $11M so far. https://endpoints.news/exclusive-robotics-startup-medra-raises-11m-to-automate-labs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/exclusive-robotics-startup-medra-raises-11m-to-automate-labs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1966178753408868758)  2025-09-11T16:35Z 30.4K followers, [----] engagements


"KalVista reports strong sales of its hereditary angioedema drug but Wall Street analysts caution maintaining momentum is reliant on refills. https://endpoints.news/kalvista-reports-strong-sales-in-early-launch-of-hereditary-angioedema-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/kalvista-reports-strong-sales-in-early-launch-of-hereditary-angioedema-drug/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1966507448107241837)  2025-09-12T14:21Z 30.4K followers, [----] engagements


"On Monday Summit's less-than-ideal results for its bispecific drug left Wall Street shaken up and questioning if bispecifics could work on their own. Enter Pfizer. https://endpoints.news/pfizer-has-a-vegf-bispecific-strategy-and-its-very-different-than-summits/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/pfizer-has-a-vegf-bispecific-strategy-and-its-very-different-than-summits/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1966564567804149798)  2025-09-12T18:08Z 30.5K followers, [----] engagements


"Novartis is on a🔥deal-making🔥spree the return to Monte Rosa being the latest one and worth more than $5.7B in biobucks. Monte Rosa's $GLUE soared this morning. https://endpoints.news/novartis-extends-deal-spree-with-120m-for-monte-rosas-immune-degraders/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novartis-extends-deal-spree-with-120m-for-monte-rosas-immune-degraders/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1967578350215675990)  2025-09-15T13:16Z 30.5K followers, [----] engagements


"Lila Sciences officially announced that it raised $235M to build "scientific superintelligence" and plans to use the funds to scale up. https://endpoints.news/ai-startup-lila-sciences-raises-235m-series-a/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/ai-startup-lila-sciences-raises-235m-series-a/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1967614543322103963)  2025-09-15T15:40Z 30.4K followers, [----] engagements


"Over the weekend Endpoints scooped that Lila was near a major raise and a $1B+ valuation. One source told us the company could add more funds to Monday's Series A"  
[X Link](https://x.com/endpts/status/1967614698536468916)  2025-09-15T15:41Z 30.4K followers, [---] engagements


"Genmab stopped development of an early-stage antibody-drug conjugate from its $1.8B ProfoundBio acquisition last year a spokesperson has confirmed. https://endpoints.news/genmab-ends-work-on-adc-from-1-8b-acquisition-of-profoundbio/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/genmab-ends-work-on-adc-from-1-8b-acquisition-of-profoundbio/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1967947063922172281)  2025-09-16T13:41Z 30.6K followers, [----] engagements


"Which digital health tools are worth the cost with Caroline Pearson https://x.com/i/broadcasts/1MYxNlvAZPzGw https://x.com/i/broadcasts/1MYxNlvAZPzGw"  
[X Link](https://x.com/endpts/status/1967966757458678222)  2025-09-16T15:00Z 30.4K followers, [---] engagements


"Eli Lilly chose Richmond VA for a $5B API plant the first of four US sites tied to its $27B pledge to expand domestic drug manufacturing. https://endpoints.news/eli-lilly-picks-virginia-for-5b-api-site-as-part-of-27b-us-pledge/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/eli-lilly-picks-virginia-for-5b-api-site-as-part-of-27b-us-pledge/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1968045501062025612)  2025-09-16T20:13Z 30.5K followers, [----] engagements


"Exclusive: GHO Capital has acquired tapping into the trend of drugmakers outsourcing R&D through digital platforms rather than building in-house. https://endpoints.news/gho-capital-buys-scientist-com-provider-of-a-drug-development-marketplaceutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= http://Scientist.com https://endpoints.news/gho-capital-buys-scientist-com-provider-of-a-drug-development-marketplaceutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= http://Scientist.com"  
[X Link](https://x.com/endpts/status/1968060907906535698)  2025-09-16T21:14Z 30.4K followers, [----] engagements


"Roche is acquiring 89bio betting on FGF21 drug pegozafermin to grow its fatty liver and cardiometabolic portfolio. https://endpoints.news/roche-to-enter-fgf21-space-via-2-4b-buyout-of-mash-biotech-89bio/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/roche-to-enter-fgf21-space-via-2-4b-buyout-of-mash-biotech-89bio/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1968701437694689583)  2025-09-18T15:39Z 30.4K followers, [---] engagements


"Bob Langer is backing a new VC firm T.Rx Capital which just closed its first fund at $77.5M a rare launch in todays tighter biotech funding climate. https://endpoints.news/life-sciences-vc-firm-with-bob-langer-as-chair-closes-77m-inaugural-fund/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/life-sciences-vc-firm-with-bob-langer-as-chair-closes-77m-inaugural-fund/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1968737277560934484)  2025-09-18T18:01Z 30.5K followers, [----] engagements


"Judo Bio https://endpoints.news/endpoints-11-winner-2025-judo-bio-broadens-the-reach-of-rna-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/endpoints-11-winner-2025-judo-bio-broadens-the-reach-of-rna-drugs/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1969042806216741365)  2025-09-19T14:16Z 30.4K followers, [--] engagements


"Lila Sciences https://endpoints.news/endpoints-11-winner-2025-lila-sciences-will-let-scientific-superintelligence-run-the-lab/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/endpoints-11-winner-2025-lila-sciences-will-let-scientific-superintelligence-run-the-lab/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1969042808297165245)  2025-09-19T14:16Z 30.4K followers, [---] engagements


"Avanzo has raised another $60M in a Series B for four cancer treatments licensed from China. https://endpoints.news/avenzo-collects-another-60m-for-two-small-molecules-and-two-adcs-licensed-from-china/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/avenzo-collects-another-60m-for-two-small-molecules-and-two-adcs-licensed-from-china/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1970176603775758768)  2025-09-22T17:21Z 30.5K followers, [----] engagements


"Sanofi is adding $625M to its venture arm bringing total fund size to $1.4B as it doubles down on biotech bets amid a tighter funding landscape. https://endpoints.news/sanofi-adds-625m-to-its-corporate-venture-arm/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/sanofi-adds-625m-to-its-corporate-venture-arm/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1970859600003145872)  2025-09-24T14:35Z 30.6K followers, [----] engagements


"UniQures gene therapy slowed Huntingtons by 75% in a Ph1/2 trial. With an FDA filing planned for early [----] its eyeing a potential launch next year. https://endpoints.news/uniqure-unwraps-phase-1-2-gene-therapy-data-for-huntingtons-disease/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/uniqure-unwraps-phase-1-2-gene-therapy-data-for-huntingtons-disease/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1970876492985839943)  2025-09-24T15:42Z 30.5K followers, [----] engagements


"Merck KGaA CEO Beln Garijo will step down in May [----]. Electronics unit head Kai Beckmann is set to take the helm after [--] years with the company. https://endpoints.news/merck-kgaa-ceo-belen-garijo-to-leave-next-may-when-electronics-unit-leader-will-take-the-helm/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/merck-kgaa-ceo-belen-garijo-to-leave-next-may-when-electronics-unit-leader-will-take-the-helm/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1971236515671085482)  2025-09-25T15:33Z 30.5K followers, [---] engagements


"🚨 Breaking news on the White House's "most favored nation" plans: An @endpts exclusive: The White House is weighing a broad drug pricing event as soon as next week that would include MFN-related price cuts an update on Medicare negotiations through the IRA and multiple CMMI drug pricing demos. With @ArmstrongDrew: https://t.co/nGQMhoOrl8 An @endpts exclusive: The White House is weighing a broad drug pricing event as soon as next week that would include MFN-related price cuts an update on Medicare negotiations through the IRA and multiple CMMI drug pricing demos. With @ArmstrongDrew:"  
[X Link](https://x.com/endpts/status/1971325662024831393)  2025-09-25T21:27Z 30.5K followers, [----] engagements


"Scott Gottlieb on what it would take to compete with China's biotech rise https://x.com/i/broadcasts/1nAKEEonydXKL https://x.com/i/broadcasts/1nAKEEonydXKL"  
[X Link](https://x.com/endpts/status/1971613257195831489)  2025-09-26T16:30Z 30.5K followers, 43K engagements


"AstraZeneca is planning to list its shares directly on NYSE in an effort to "harmonise its share listing structure". https://endpoints.news/astrazeneca-plans-direct-new-york-listing-in-another-blow-to-uk-life-sciences/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/astrazeneca-plans-direct-new-york-listing-in-another-blow-to-uk-life-sciences/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1972727578202177905)  2025-09-29T18:18Z 30.5K followers, [----] engagements


"AbbVie Novartis and Boehringer unveiled drug pricing concessions as Trumps 'most favored nation' deadline pushes pharmas to act by Sept. [--]. https://endpoints.news/white-house-deadline-brings-flurry-of-pharma-price-cutdowns/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/white-house-deadline-brings-flurry-of-pharma-price-cutdowns/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1972782775062429838)  2025-09-29T21:57Z 30.6K followers, [----] engagements


"Star Therapeutics just banked a $125M Series D to push its bleeding disorder candidate into Phase [--] betting the space could be pharmas next big frontier. https://endpoints.news/star-gets-125m-series-d-as-it-begins-phase-3-in-bleeding-disorders/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/star-gets-125m-series-d-as-it-begins-phase-3-in-bleeding-disorders/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1973054124267606231)  2025-09-30T15:55Z 30.6K followers, [----] engagements


"After Ochre Bio Jack OMeara is back with Aerska a neuro-focused biotech that just raised $21M to speed siRNAs into the clinic. https://endpoints.news/after-building-ochre-bio-jack-omearas-newest-biotech-raises-21m-for-neuro-sirnasutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/after-building-ochre-bio-jack-omearas-newest-biotech-raises-21m-for-neuro-sirnasutm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1973398899197903013)  2025-10-01T14:45Z 30.6K followers, [----] engagements


"Wall Street sees Pfizers drug pricing deal with Trump as a win with $PFE shares up 15% on Wednesday as analysts say it could offer a roadmap for other pharma companies. https://endpoints.news/pfizer-white-house-deal-prompts-pharma-rally-on-wall-street/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/pfizer-white-house-deal-prompts-pharma-rally-on-wall-street/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1973487125208375588)  2025-10-01T20:36Z 30.6K followers, [----] engagements


"Exclusive: Cirrus Therapeutics launched with $11M to develop a gene therapy for dry age-related macular degeneration aiming to slow vision loss by boosting an immune protein in the eye. https://endpoints.news/gene-therapy-startup-launches-with-11m-to-tackle-aging-disease-of-the-eye/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/gene-therapy-startup-launches-with-11m-to-tackle-aging-disease-of-the-eye/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1973782950551708082)  2025-10-02T16:11Z 30.6K followers, [----] engagements


"New SEC docs reveal how Roches $2.4B buyout of 89bio came together with no rival bids rising offers and years of relationship building. https://endpoints.news/roche-was-the-only-pharma-to-make-an-acquisition-offer-for-89bio/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/roche-was-the-only-pharma-to-make-an-acquisition-offer-for-89bio/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1973821125479313710)  2025-10-02T18:43Z 30.5K followers, [----] engagements


"Biotech IPOs in Hong Kong are booming with over [--] filings this year more than 4x the US as Chinas biotech sector outpaces a sluggish US market. https://endpoints.news/biotech-ipos-in-hong-kong-far-outpace-the-us-driven-by-chinas-buzzy-biotech-sector/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/biotech-ipos-in-hong-kong-far-outpace-the-us-driven-by-chinas-buzzy-biotech-sector/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1973853310005506341)  2025-10-02T20:51Z 30.5K followers, [----] engagements


"🎙 Join us LIVE today at 2pm ET🎙 @vijaypande will sit with @AndrewE_Dunn to discuss life after a16z and what's next with AI in the bio world. https://endpoints.news/post-hoc-live-vijay-pande-talks-ai-bio-starting-new-fund-vzvc-after-a16z/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/post-hoc-live-vijay-pande-talks-ai-bio-starting-new-fund-vzvc-after-a16z/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1975528064676217217)  2025-10-07T11:46Z 30.6K followers, [----] engagements


"Zooming out on AI in biopharma with Vijay Pande https://x.com/i/broadcasts/1YpKkkjpbABKj https://x.com/i/broadcasts/1YpKkkjpbABKj"  
[X Link](https://x.com/endpts/status/1975622125043228769)  2025-10-07T17:59Z 30.6K followers, [----] engagements


"AstraZeneca scores a win in its mid-stage trial for its hypertension candidate. https://endpoints.news/astrazenecas-hypertension-pill-scores-second-late-stage-win/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/astrazenecas-hypertension-pill-scores-second-late-stage-win/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1975645488914264326)  2025-10-07T19:32Z 30.6K followers, [----] engagements


"Novo Nordisk spending $4.7B to buy MASH specialist Akero. https://endpoints.news/novo-nordisk-to-buy-mash-player-akero-for-4-7b-upfront/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/novo-nordisk-to-buy-mash-player-akero-for-4-7b-upfront/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1976295623813992635)  2025-10-09T14:36Z 30.6K followers, [----] engagements


"This week's Peer Review has landed: Former CSO at Shape moves to Moderna as CTO; Eli Lilly scoops up former FDA official Peter Marks; and there are a flurry of changes happing at the FDA. Get the full rundown: https://endpoints.news/shapes-interim-ceo-picks-up-tech-role-at-moderna-lilly-reels-in-peter-marks/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/shapes-interim-ceo-picks-up-tech-role-at-moderna-lilly-reels-in-peter-marks/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1976647406755422230)  2025-10-10T13:54Z 30.6K followers, [----] engagements


"Excellergy has high ambitions to treat allergies and inflammation. Its experimental drugs "effector cell response inhibitors ECRIs for shortcould treat anything from food allergies to eczema. https://endpoints.news/excellergy-debuts-with-70m-series-a-and-plan-to-take-on-xolair/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/excellergy-debuts-with-70m-series-a-and-plan-to-take-on-xolair/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1977824529499238910)  2025-10-13T19:51Z 30.6K followers, [----] engagements


"Lila Sciences closed a $350M Series A to advance its AI-doing-science vision connecting models to experiments to create scientific superintelligence. https://endpoints.news/lila-sciences-closes-350m-series-a-bringing-in-nvidia/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= https://endpoints.news/lila-sciences-closes-350m-series-a-bringing-in-nvidia/utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content="  
[X Link](https://x.com/endpts/status/1978203640478224672)  2025-10-14T20:57Z 30.6K followers, [----] engagements


"Pfizer Raised Prices on [---] Drugs This Year And It's Not Alone http://t.co/8C9U2gW1r1 via @ZTracer http://t.co/ijr6hUjgaU http://www.bloomberg.com/news/articles/2015-10-02/pfizer-raised-prices-on-133-drugs-this-year-and-it-s-not-alone http://Bloomberg.com http://www.bloomberg.com/news/articles/2015-10-02/pfizer-raised-prices-on-133-drugs-this-year-and-it-s-not-alone http://Bloomberg.com"  
[X Link](https://x.com/endpts/status/651065847448862721)  2015-10-05T16:06Z 29.4K followers, [--] engagements


"Stock Quote SRPT Sarepta Therapeutics Inc. h/t @BioRunUp http://finviz.com/quote.ashxt=srpt http://finviz.com/quote.ashxt=srpt"  
[X Link](https://x.com/endpts/status/753231706157527040)  2016-07-13T14:16Z 29.2K followers, [--] engagements


"Looks like $PFE is closing in on the buyout that $MDVN CEO David Hung wanted by @JohnCendpts http://endpts.com/ft-pfizer-is-closing-in-on-a-medivation-buyout-with-blowout-14b-offer/ http://endpts.com/ft-pfizer-is-closing-in-on-a-medivation-buyout-with-blowout-14b-offer/"  
[X Link](https://x.com/endpts/status/767493165775454208)  2016-08-21T22:46Z 29.3K followers, [--] engagements


"Powerful Dems orchestrated campaign at #FDA to provide $BIIB drug to dying fundraiser @billclinton #PodestaEmails http://endpts.com/powerful-pols- http://endpts.com/powerful-pols-"  
[X Link](https://x.com/endpts/status/787414783024730112)  2016-10-15T22:08Z 29.4K followers, [--] engagements


"$PFE inks an early-stage collaboration deal as it invests in another startup; #Stemcell #startup lands cardiac tech https://endpts.com/pfizer-inks-an-early-stage-collaboration-deal-as-it-invests-in-another-startup-stem-cell-startup-lands-cardiac-tech/ https://endpts.com/pfizer-inks-an-early-stage-collaboration-deal-as-it-invests-in-another-startup-stem-cell-startup-lands-cardiac-tech/"  
[X Link](https://x.com/endpts/status/809339721289789440)  2016-12-15T10:10Z 29.3K followers, [--] engagements


"Pfizer Merck KGaA run into a severe setback as PD-L1 drug Bavencio fails in PhIII gastric cancer study #biotech https://endpts.com/pfizer-merck-kgaa-run-into-a-severe-setback-as-pd-l1-drug-bavencio-fails-in-phiii-gastric-cancer-study/ https://endpts.com/pfizer-merck-kgaa-run-into-a-severe-setback-as-pd-l1-drug-bavencio-fails-in-phiii-gastric-cancer-study/"  
[X Link](https://x.com/endpts/status/935506232198262784)  2017-11-28T13:50Z 29.4K followers, [--] engagements


"In a blow to Eli Lilly Novo Nordisk lands #FDA OK for their next big entry in the #diabetes market: Ozempic #drugapproval https://endpts.com/with-a-phiii-obesity-trial-looming-novo-nordisk-lands-fda-ok-for-their-next-big-entry-in-the-diabetes-market-ozempic/ https://endpts.com/with-a-phiii-obesity-trial-looming-novo-nordisk-lands-fda-ok-for-their-next-big-entry-in-the-diabetes-market-ozempic/"  
[X Link](https://x.com/endpts/status/938364902909136897)  2017-12-06T11:10Z 29.4K followers, [--] engagements


"Ex-Pfizer CEOs startup Centrexion gets $67M for PhIII #painkiller https://endpts.com/ex-pfizer-ceos-startup-centrexion-gets-67m-for-phiii-painkiller/ https://endpts.com/ex-pfizer-ceos-startup-centrexion-gets-67m-for-phiii-painkiller/"  
[X Link](https://x.com/endpts/status/948177765177679873)  2018-01-02T13:02Z 29.4K followers, [--] engagements


"Pfizer lines up an $830M alliance with Arvinas on protein degradation https://endpts.com/pfizer-lines-up-an-830m-alliance-with-arvinas-on-protein-degradation/ https://endpts.com/pfizer-lines-up-an-830m-alliance-with-arvinas-on-protein-degradation/"  
[X Link](https://x.com/endpts/status/948782309456662531)  2018-01-04T05:05Z 29.3K followers, [--] engagements


"Pfizer lines up an $830M alliance with Arvinas on protein degradation #biotech #vc https://endpts.com/pfizer-lines-up-an-830m-alliance-with-arvinas-on-protein-degradation/ https://endpts.com/pfizer-lines-up-an-830m-alliance-with-arvinas-on-protein-degradation/"  
[X Link](https://x.com/endpts/status/949048798533378048)  2018-01-04T22:44Z 29.4K followers, [--] engagements


"Axovant shares blasted as Vivek Ramaswamys premier drug proves worthless second drug misses key goal https://endpts.com/axovant-shares-blasted-as-vivek-ramaswamys-premier-drug-proves-worthless-second-drug-misses-key-goal/ https://endpts.com/axovant-shares-blasted-as-vivek-ramaswamys-premier-drug-proves-worthless-second-drug-misses-key-goal/"  
[X Link](https://x.com/endpts/status/950363517609218049)  2018-01-08T13:48Z 29.4K followers, [--] engagements


"Pfizer oncology head Liz Barrett jumps ship to Novartis $PFE $NVS https://endpts.com/pfizer-oncology-head-liz-barrett-jumps-ship-to-novartis-as-bruno-strigini-retires/ https://endpts.com/pfizer-oncology-head-liz-barrett-jumps-ship-to-novartis-as-bruno-strigini-retires/"  
[X Link](https://x.com/endpts/status/951412618996207616)  2018-01-11T11:16Z 29.3K followers, [--] engagements


"Beefing up its CAR-T pipeline Gilead teams up with Pfizer on a #lymphoma combo https://endpts.com/beefing-up-its-car-t-pipeline-gilead-teams-up-with-pfizer-on-a-lymphoma-combo/ https://endpts.com/beefing-up-its-car-t-pipeline-gilead-teams-up-with-pfizer-on-a-lymphoma-combo/"  
[X Link](https://x.com/endpts/status/954000415812661255)  2018-01-18T14:39Z 29.4K followers, [--] engagements


"Pfizer vs J&J: Researchers are duking it out for the championship title in nonmetastatic prostate cancer $PFE $JNJ https://endpts.com/pfizer-vs-jj-researchers-are-duking-it-out-for-the-championship-title-in-nonmetastatic-prostate-cancer/ https://endpts.com/pfizer-vs-jj-researchers-are-duking-it-out-for-the-championship-title-in-nonmetastatic-prostate-cancer/"  
[X Link](https://x.com/endpts/status/961007596101611520)  2018-02-06T22:44Z 29.3K followers, [--] engagements


"GSK drops out of $20B race for Pfizers consumer health unit shares surge $GSK $PFE https://endpts.com/gsk-drops-out-of-race-for-pfizers-consumer-health-unit-shares-surge/ https://endpts.com/gsk-drops-out-of-race-for-pfizers-consumer-health-unit-shares-surge/"  
[X Link](https://x.com/endpts/status/977164930934870016)  2018-03-23T12:47Z 29.3K followers, [--] engagements


"Pfizers $PFE PhIII kidney cancer study for Inlyta flops as investigators flag a dead end on outcomes https://endpts.com/pfizers-phiii-kidney-cancer-study-for-inlyta-flops-as-investigators-flag-a-dead-end-on-outcomes/ https://endpts.com/pfizers-phiii-kidney-cancer-study-for-inlyta-flops-as-investigators-flag-a-dead-end-on-outcomes/"  
[X Link](https://x.com/endpts/status/983782397996093440)  2018-04-10T19:02Z 29.3K followers, [--] engagements


"AstraZenecas star respiratory drug runs into another wall with COPD but its not giving up yet https://endpts.com/astrazenecas-star-respiratory-drug-runs-into-another-wall-with-copd-but-its-not-giving-up-yet/ https://endpts.com/astrazenecas-star-respiratory-drug-runs-into-another-wall-with-copd-but-its-not-giving-up-yet/"  
[X Link](https://x.com/endpts/status/994882207813685250)  2018-05-11T10:09Z 29.4K followers, [--] engagements


"Polyphor parlays a pathogen-specific antibiotic and I/O work into a $165M IPO for its PhIII program https://endpts.com/polyphor-parlays-a-pathogen-specific-antibiotic-and-i-o-work-into-a-165m-ipo-for-its-phiii-program/ https://endpts.com/polyphor-parlays-a-pathogen-specific-antibiotic-and-i-o-work-into-a-165m-ipo-for-its-phiii-program/"  
[X Link](https://x.com/endpts/status/996338162107641856)  2018-05-15T10:35Z 29.3K followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing